Health Care & Life Sciences » Biotechnology | Chiome Bioscience Inc.

Chiome Bioscience Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
424,813.00
885,525.00
1,280,695.00
1,501,280.00
880,150.00
1,531,082
Depreciation, Depletion & Amortization
55,455.00
80,758.00
102,368.00
113,102.00
10,593.00
7,016
Other Funds
-
-
3,578.00
18,233.00
-
862
Funds from Operations
360,970.00
802,404.00
1,149,963.00
972,497.00
872,060.00
1,524,925
Changes in Working Capital
12,288.00
13,078.00
95,362.00
2,591.00
4,859.00
163,788
Net Operating Cash Flow
373,258.00
789,326.00
1,245,325.00
969,906.00
867,201.00
1,688,713
Capital Expenditures
42,801.00
118,946.00
168,054.00
10,955.00
4,975.00
Sale of Fixed Assets & Businesses
-
13,734.00
-
-
2,051.00
Purchase/Sale of Investments
-
499,887.00
1,612,461.00
1,999,432.00
125,490.00
Net Investing Cash Flow
114,786.00
618,833.00
1,780,059.00
1,988,626.00
137,113.00
Issuance/Reduction of Debt, Net
47,915.00
50,812.00
100,001.00
45,837.00
50,004.00
Net Financing Cash Flow
463,473.00
2,130,818.00
124,262.00
1,433,831.00
478,603.00
Net Change in Cash
24,550.00
726,191.00
2,901,122.00
2,452,551.00
525,711.00
Free Cash Flow
416,059.00
893,887.00
1,409,114.00
980,361.00
872,176.00
Other Sources
-
12,239.00
456.00
150.00
-
Change in Capital Stock
415,558.00
2,151,630.00
20,683.00
1,461,435.00
528,607.00
Exchange Rate Effect
21.00
3,532.00
-
-
-
Other Uses
71,985.00
6,629.00
-
-
8,700.00

About Chiome Bioscience

View Profile
Address
Sumitomo Fudosan Nishi-Shinjuku Bldg
Tokyo Tokyo 151
Japan
Employees -
Website http://www.chiome.co.jp
Updated 07/08/2019
Chiome Bioscience, Inc. engages in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) System. Its operations are carried out through Innovative Drug and Innovative Drug Support business segments. The Innovative Drug segment manufactures specific antibodies based on new antigen mechanisms and licenses these out to pharmaceutical industries.